As mentioned earlier, p53 activation through acetylation caused by SIRT1 inhibition diminished the number of CML LSCs when the SIRT1 inhibitor was used in combination with a TKI53. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.